A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

Peking Union Medical College Hospital ( Site 3304), Bejiing

Beijing Cancer Hospital ( Site 3314), Beining

Beijing Tongren Hospital affiliated to Capital Medical University ( Site 3343), Beijing

Jilin Cancer Hospital ( Site 3310), Changchun

The Third Affiliated Hospital of Harbin Medical University ( Site 3302), Harbin

Shanghai 9th People hospital ( Site 3332), Shanghai

Fudan University Shanghai Cancer Center ( Site 3324), Shanghai

Shanghai East Hospital ( Site 3300), Shanghai

Changzhou Tumor Hospital - Changzhou Fourth People's Hospital ( Site 3339), Changzhou

Anhui Cancer Hospital-Radiology Department ( Site 3333), Hefei

Tianjin Medical University Cancer Hospital ( Site 3312), Tianjin

Zhejiang Cancer Hospital ( Site 3303), Hangzhou

Jiangxi Cancer Hospital ( Site 3313), Nanchang

Fujian Provincial Cancer Hospital ( Site 3326), Fuzhou

Chongqing Cancer Hospital ( Site 3327), Chongqing

Hunan Cancer Hospital ( Site 3311), Changsha

Xiangya Hospital of Central South University ( Site 3305), Changsha

Hunan Cancer Hospital ( Site 3334), Changsha

Wuhan Union hospital Cancer Center ( Site 3307), Wuhan

Tongji Hospital Tongji Medical,Science & Technology ( Site 3316), Wuhan

Henan Cancer Hospital ( Site 3309), Zhengzhou

Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 3336), Guangzhou

Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 3338), Guangzhou

The First Affiliated Hospital, Sun Yat-sen University ( Site 3344), Guangzhou

Guangxi Medical University Affiliated Tumor Hospital ( Site 3322), Nanning

Guizhou Cancer Hospital ( Site 3330), Guiyang

West China Hospital of Sichuan University ( Site 3308), Chengdu

The First Affiliated Hospital of Xi an Jiaotong University ( Site 3328), Xi'an